SB 242235

SB-242235 is a potent and selective p38 MAP kinase inhibitor, with an IC50 of 1.0　μM in primary human chondrocytes[1].

Product Specifications

CAS Number

[193746-75-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; p38 MAPK

Type

Reference compound

Related Pathways

Autophagy; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/SB-242235.html

Concentration

10mM

Purity

99.67

Solubility

DMSO : ≥ 48 mg/mL

Smiles

COC1=NC=CC(C2=C(C3=CC=C(F)C=C3)N=CN2C4CCNCC4)=N1

Molecular Formula

C19H20FN5O

Molecular Weight

353.39

Precautions

H302, H315, H319, H335

References & Citations

[1]Badger, A.M., et al., Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures. Osteoarthritis Cartilage, 2000. 8 (6) : p. 434-43.|[2]Kim AL , et al. Role of p38 MAPK in UVB-induced inflammatory responses in the skin of SKH-1 hairless mice. J Invest Dermatol. 2005 Jun;124 (6) :1318-25.|[3]Ward, K.W., et al., SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. I: preclinical pharmacokinetics. Xenobiotica, 2002. 32 (3) : p. 221-33.